{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 147 of 169', 'CROs/vendors', 'Service', 'Name and address', 'Data management', 'Quanticate Ltd.', 'Bevan House, 9-11 Bancroft Court, Hitchin, Hertfordshire', 'SG5 1LH', 'United Kingdom', 'ePRO', 'CRF Health Management Ltd.', '3rd Floor, Brook House, 229-243 Shepherds Bush Road,', 'Hammersmith, London W6 7AN', 'United Kingdom', 'ECG', 'Cardiabase S.A.S.', 'Villa Alsacienne, 78 Avenue du XXe Corps, 54000 Nancy', 'France', 'Central Lab', 'ACM Global Central Laboratory', '23 Hospital Fields Road, York YO10 4DZ', 'United Kingdom', 'PK analysis and ADA', 'Covance Laboratories Ltd.', 'Otley Road, Harrogate, North Yorkshire, HG3 IPY', 'United Kingdom', 'Photography', 'Canfield Scientific, Inc.', '253 Passaic Ave., Fairfield, NJ 07004', 'United States of America', 'IWRS', 'Quanticate Ltd.', 'Bevan House, 9-11 Bancroft Court, Hitchin, Hertfordshire', 'SG5 1LH', 'United Kingdom', 'CMO', 'Almac Clinical Services Ltd.', 'Almac House, 20 Seagoe Industrial Estate, Craigavon BT63', '5QD, United Kingdom', 'CRO services in Japan', 'intellim Corporation', '18F, Mainichi Intecio, 3-4-5 Umeda, Kita-ku, Osaka 530-0001', 'Japan', 'Emergency unblinding CRO', 'C3i, Inc.', '25 Lindsley Drive, Morristown, NJ 07960', 'United States of America', 'Microbiology', 'AROS Applied Biotechnology A/S', 'Palle Juul-Jensens Boulevard 82, DK-8200 Aarhus N', 'Denmark', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 148 of 169', 'Service', 'Name and address', 'Biomarkers (IL-13, IL-17 and', 'Eurofins Pharma Bioanalytics Services US Inc.', 'IL-22 serum analysis)', '15 Research Park Drive, St. Charles, MO 63304', 'United States of America', 'Biomarkers (other serum', 'Eurofins Pharma Bioanalysis Services UK Ltd.', 'biomarkers)', '90 Park Drive, Milton Park, Abingdon, OX14 4RY', 'United Kingdom', 'Skin biopsies (gene expression', 'AROS Applied Biotechnology A/S', 'analysis)', 'Palle Juul-Jensens Boulevard 82, DK-8200 Aarhus N', 'Denmark', 'Trial committees', 'Data Monitoring Committee', 'Role', 'Name', 'Chairman', 'PPD', ', Dr. med. Dr. phil.', 'Technical University of Munich, Germany', 'Member', 'PPD', ', MD', 'University of Michigan, USA', 'Member', 'PPD', ',', 'BSc MSc CStat CSci', 'S-cubed Biometrics Ltd, UK', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 149 of 169', 'Appendix 9: WHO model prescribing information for classification of', 'topical corticosteroids', 'Hydrocortisone and betamethasone are examples of low- and high-potency topical', 'corticosteroids (TCS). TCS have been ranked in terms of potency into 4 groups consisting of', '7 classes. Class ITCS are the most potent and Class VII TCS are the least potent (Panel 17).', 'Efficacy and side-effects are greatest with the Class I ultra-high-potency preparations which', 'should only be used for limited time periods (2-3 weeks).', 'Representative preparations by group are listed in the table below according to the WHO', 'model prescribing information for drugs used in skin diseases (41). These groups may vary', 'depending on the formulation and concentration and should be considered approximate. In', 'general, ointments are more potent than creams or lotions. Potency is also increased when', 'TCS are used under occlusive dressings or in intertriginous areas.', 'Panel 17 Classification of topical corticosteroids', 'Potency', 'Class', 'Topical corticosteroid', 'Formulation', 'Ultra high', 'I', 'Clobetasol propionate', 'Cream, 0.05%', 'Diflorasone diacetate', 'Ointment, 0.05%', 'High', 'II', 'Amcinonide', 'Ointment, 0.1%', 'Betamethasone dipropionate', 'Ointment, 0.05%', 'Desoximetasone', 'Cream or ointment, 0.025%', 'Fluocinonide', 'Cream, ointment, or gel, 0.05%', 'Halcinonide', 'Cream, 0.1%', 'III', 'Betamethasone dipropionate', 'Cream, 0.05%', 'Betamethasone valerate', 'Ointment, 0.1%', 'Diflorasone diacetate', 'Cream, 0.05%', 'Triamcinolone acetonide', 'Ointment, 0.1%', 'Moderate', 'IV', 'Desoximetasone', 'Cream, 0.05%', 'Fluocinolone acetonide', 'Ointment, 0.025%', 'Fludroxycortide', 'Ointment, 0.05%', 'Hydrocortisone valerate', 'Ointment, 0.2%', 'Triamcinolone acetonide', 'Cream, 0.1%', 'V', 'Betamethasone dipropionate', 'Lotion, 0.02%', 'Betamethasone valerate', 'Cream, 0.1%', 'Fluocinolone acetonide', 'Cream, 0.025%', 'Fludroxycortide', 'Cream, 0.05%', 'Hydrocortisone butyrate', 'Cream, 0.1%', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}